Total (n=285) SCE [-] (n=219) SCE [+] (n=66) P value (SCE[-] vs. SCE [+])
Age, y 63±12 62±12 66±10 0.029
Male, n (%) 208 (73) 158 (72) 50 (76) 0.560
BMI, kg/m2 23.8±3.6 23.7±3.6 24.1±3.4 0.505
Persistent AF, n (%) 131 (446) 92 (42) 39 (59) 0.015
CHADS2 score, pts 1.2±1.2 1.1±1.1 1.6±1.3 0.003
CHA2DS2-VASc score, pts 2.1±1.6 2.0±1.5 2.6±1.7 0.008
CHF, n (%) 79 (28) 58 (26) 21 (32) 0.401
HT, n (%) 121 (43) 90 (41) 31 (47) 0.399
Age ≥65, n (%) 150 (53) 110 (50) 40 (61) 0.137
Age ≥75, n (%) 43 (15) 29 (13) 14 (21) 0.125
DM, n (%) 48 (17) 32 (15) 16 (24) 0.076
Stroke/TIA, n (%) 31 (11) 19 (9) 12 (18) 0.039
Vascular disease, n (%) 13 (5) 8 (4) 5 (8) 0.208
Blood test
AST, IU/L 22.3±11.3 21.8±10.0 24.2±15.1 0.132
ALT, IU/L 21.5±18.9 21.8±20.7 20.7±10.8 0.689
Cr, mg/dl 0.84±0.2 0.84±0.2 0.86±0.2 0.622
CrCl, ml/min 84.5±29.3 85.5±29.3 81.0±29.5 0.271
NT-ProBNP, pg/ml 529±667 483±686 676±603 0.049
PT-INR 1.52±0.82 1.53±0.06 1.51±0.10 0.912
APTT, sec 42.5±10.1 42.5±8.8 42.7±14.9 0.883
TTE findings
LVDd, mm 46.8±6.4 46.7±6.5 46.8±6.2 0.929
LVDs, mm 32.1±7.9 32.0±7.7 32.5±8.3 0.684
EF, % 55.8±9.5 55.8±0.6 55.8±1.2 0.984
LAD, mm 38.6±6.9 38.1±7.2 40.4±5.7 0.013
TEE findings
AF at TEE, n (%) 130 (46) 93 (42) 37 (56) 0.052
SEC, n (%) 56 (20) 32 (15) 24 (36) <0.001
LAA flow velocity, cm/s 53.2±22.2 54.3±22.3 49.2±22.3 0.101
Oral anticoagulants
Dabigatran, n (%) 85 (29) 67 (31) 18 (27) 0.307
Rivaroxaban, n (%) 59 (21) 46 (21) 13 (20)
Apixaban, n (%) 48 (17) 32 (15) 16 (24)
Edoxaban, n (%) 56 (20) 47 (21) 9 (14)
Warfarin, n (%) 37 (13) 27 (12) 10 (15)
Low dose in NOACs, n (%) 44 (18) 32 (17) 12 (21) 0.420
IDR in NOACs, n (%) 14 (5) 11 (6) 3 (5) 0.915
Medication
Beta-blocker, n (%) 147 (52) 110 (50) 37 (56) 0.405
Diuretics, n (%) 53 (18) 41 (19) 12 (18) 0.921
ACEI/ARB, n (%) 79 (27) 57 (26) 22 (33) 0.251
Statin, n (%) 62 (22) 46 (21) 16 (24) 0.580
Antiplatelet, n (%) 21 (7) 17 (8) 4 (6) 0.636
AAD, n (%) 39 (15) 26 (12) 13 (20) 0.118
Procedure
RFCA, n (%) 181 (71) 134 (68) 47 (80) 0.070
Cryoballoon ablation, n (%) 74 (29) 62 (84) 12 (16)
Additional linear ablation 52 (18) 37 (17) 15 (23) 0.292
No. of ECV/patients, n 2.6±3.2 2.6±3.1 2.6±3.5 0.953
UFH/ACT kinetics
Baseline ACT, sec 154±29 156±29 146±27 0.024
Time to reach optimal ACT, sec 37±26 35±25 44±30 0.018
Amount of UFH to reach optimal ACT, IU 6947±2880 6894±2928 7121±2714 0.576
Total amount of UFH, IU 10162±3838 10096±3848 10385±3807 0.595